Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare...

Read More